Drug
Afatinib Dimaleate
Afatinib Dimaleate: highest development phase Phase 1, developed by Merck. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Merck
Trials
| Drug | Phase | Indication |
|---|---|---|
| Afatinib Dimaleate NCT02364609 | Phase 1 | Recurrent Non-Small Cell Lung Carcinoma |
Latest
No recent events.
Follow Afatinib Dimaleate on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.